Pergamum completes patient recruitment to the Phase II clinical trial for prevention of post-surgical adhesions
(Thomson Reuters ONE) -
SWEDEN, STOCKHOLM - February 10, 2012. Pergamum AB announced today that the last
patient has been dosed in a randomized Phase II trial of PXL01 for prevention of
post-surgical adhesions. Karolinska Development AB is the majority owner of
Pergamum.
In total, 138 patients undergoing hand surgery have been included in Pergamum's
placebo controlled, multi-center trial that has been conducted in Sweden,
Denmark and Germany. The trial evaluates the safety and effectiveness of the
novel therapeutic peptide PXL01 to improve mobility and function of the hand
after surgery. Many patients undergoing hand surgery today suffer from
debilitating scar formation which reduces the range of motion and complicates
daily activities. PXL01 is a product under development with the purpose to
reduce the formation of obstructing scars and restore mobility and function back
to the patient's normal level. The final patient will be followed-up for a
period of 12 weeks and results from the study are expected to be presented later
this year.
"It is an important milestone to be able to finalize the recruitment to this
exciting study. PXL01 has the potential of becoming, the first pharmaceutical
product registered to target post-surgical adhesions. We believe that this new
treatment concept can have a great impact on the surgical outcome, not only for
hand surgery patients but also for patients undergoing knee and shoulder
surgery, after which adhesion formation is a considerable debilitating side-
effect", said Jonas Ekblom, CEO of Pergamum.
According to a Lancet article, there are more than 230 million surgical
procedures performed in the world annually and in many of these cases the
patients are at risk for the formation of surgical adhesions. Pergamum estimates
that the global market for surgical sealants, wound closure and anti-adhesion
was in excess of USD 9bn in 2011. Currently there are no pharmaceutical products
available for prevention of adhesion. A successful Phase II trial would open up
the possibility for the development of similar treatments for a variety of
surgical procedures.
"The dermatology and wound care field represents a huge market opportunity, with
over USD 13bn in global annual sales in wound care alone, according to Espicom.
Many products on the market are old and innovation in the field has been scarce.
PXL01 is one of several innovative projects in Pergamum's pipeline aiming at
creating unique specialty care products in this area", said Torbjörn Bjerke, CEO
of Karolinska Development AB and Chairman of Pergamum AB.
For further information, please contact:
Jonas Ekblom, CEO, Pergamum AB
Phone: +46 (0)70 551 66 60, e-mail: jonas.ekblom(at)pergamum.com
Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Pergamum AB
Pergamum is a biopharmaceutical company specialized in the development of
therapeutic peptides for treatment of skin infections and wounds. Within
Pergamum, companies and projects are managed as fully integrated operating units
with access to a core team of experienced professionals within drug development
and business management. This model provides Pergamum with an attractive
diversified product pipeline while minimizing development cost and time-to-
market and mitigating risk. Three programs are currently in clinical phase. For
further information, please visit www.pergamum.com
About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 34 projects, of which 14 are in clinical development. For more
information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.
Press Release as PDF:
http://hugin.info/143071/R/1584329/495629.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1584329]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Tasman makes metallurgical Breakthrough at Norra Karr Heavy Rare Earth Element and Zirconium Project, SwedenDatum: 10.02.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 113234
Anzahl Zeichen: 5671
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pergamum completes patient recruitment to the Phase II clinical trial for prevention of post-surgical adhesions"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
